CN116583284A - 用于治疗髓性白血病的包括flt3抑制剂的药物组合物 - Google Patents

用于治疗髓性白血病的包括flt3抑制剂的药物组合物 Download PDF

Info

Publication number
CN116583284A
CN116583284A CN202180084028.6A CN202180084028A CN116583284A CN 116583284 A CN116583284 A CN 116583284A CN 202180084028 A CN202180084028 A CN 202180084028A CN 116583284 A CN116583284 A CN 116583284A
Authority
CN
China
Prior art keywords
flt3
pharmaceutical composition
methyl
leukemia
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180084028.6A
Other languages
English (en)
Chinese (zh)
Inventor
I·H·裴
J·Y·宋
J·Y·崔
Y·G·安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CN116583284A publication Critical patent/CN116583284A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180084028.6A 2020-11-05 2021-11-03 用于治疗髓性白血病的包括flt3抑制剂的药物组合物 Pending CN116583284A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2020-0147156 2020-11-05
KR20200147156 2020-11-05
PCT/KR2021/015794 WO2022098083A1 (ko) 2020-11-05 2021-11-03 Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
CN116583284A true CN116583284A (zh) 2023-08-11

Family

ID=81458079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180084028.6A Pending CN116583284A (zh) 2020-11-05 2021-11-03 用于治疗髓性白血病的包括flt3抑制剂的药物组合物

Country Status (8)

Country Link
US (1) US20260102397A1 (https=)
EP (1) EP4241773A4 (https=)
JP (1) JP7842752B2 (https=)
KR (1) KR20220061026A (https=)
CN (1) CN116583284A (https=)
CA (1) CA3197836A1 (https=)
TW (1) TW202233193A (https=)
WO (1) WO2022098083A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117586344A (zh) * 2022-08-12 2024-02-23 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531725A (zh) * 2015-08-13 2018-01-02 北京韩美药品有限公司 Irak4抑制剂及其应用
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20200102948A (ko) * 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN110229142A (zh) * 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531725A (zh) * 2015-08-13 2018-01-02 北京韩美药品有限公司 Irak4抑制剂及其应用
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20200102948A (ko) * 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIYOI HITOSHI ET AL.: ""FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development"", 《CANCER SCIENCE》, vol. 111, no. 2, 1 February 2020 (2020-02-01), pages 312 - 322, XP093197957, DOI: 10.1111/cas.14274 *
LIU DELONG ET AL.: ""Syk inhibitors in clinical development for hematological malignancies"", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》, vol. 10, no. 1, 1 December 2017 (2017-12-01), pages 1 - 7, XP093197955, DOI: 10.1186/s13045-017-0512-1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117586344A (zh) * 2022-08-12 2024-02-23 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
CN117586344B (zh) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用

Also Published As

Publication number Publication date
EP4241773A1 (en) 2023-09-13
KR20220061026A (ko) 2022-05-12
JP2023548190A (ja) 2023-11-15
CA3197836A1 (en) 2022-05-12
JP7842752B2 (ja) 2026-04-08
WO2022098083A1 (ko) 2022-05-12
EP4241773A4 (en) 2024-10-16
US20260102397A1 (en) 2026-04-16
TW202233193A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
CN116583284A (zh) 用于治疗髓性白血病的包括flt3抑制剂的药物组合物
KR102571130B1 (ko) Alk 저해제 및 shp2 저해제를 포함하는 약제학적 조합
JP6320379B2 (ja) Ｃｄｋ４／６阻害剤およびｂ−ｒａｆ阻害剤の組合せ医薬
US9408847B2 (en) Combination therapy
AU2014253348B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3038652B1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
UA125216C2 (uk) Комбінована терапія
CN105828822A (zh) 用于治疗癌症的组合疗法
KR20160020502A (ko) 제약 조합물
US10792277B2 (en) Methods of treatment of fibrosis and cancers
JP2020529418A (ja) Ｔ細胞急性リンパ芽球性白血病を治療するための化合物、組成及び方法
CN113490497A (zh) 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
JP2019524700A (ja) 癌の処置
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
KR20120133389A (ko) 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
US20050171182A1 (en) Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
WO2020227202A1 (en) Compositions and methods for treating cancer
US20240269136A1 (en) Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
US10328065B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
HK40102115A (en) Pharmaceutical composition for treating leukemia comprising flt3 inhibitor
JP2020519581A (ja) 肥満細胞疾患の処置のための方法及び医薬組成物
Zhang et al. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M‐mutant resistance in vitro and in vivo
EP4536633A1 (en) Novel ras inhibitors
JP2024531136A (ja) Ｖａｖ３がんの治療のためのｉｏｄｖａ１化合物との組み合わせ療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination